Doctor of Osteopathy Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Robert Griffin

Wyomissing, PA Doctor of Osteopathy

NPI 1528064318 CMS profile 23496

2760 Century Blvd, Wyomissing, PA 19610

Open in the dashboard

General payments

$5,562

269 records reported · program years 2019–2023

Research payments

$6,966

Paid to them · 6 records reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$669,479 paid to institutions, not to them · program years 2019–2023

Through program year 2023, Robert Griffin of Wyomissing, PA is reported in the CMS Open Payments database as having received $5,562 across 269 general payments and $6,966 in research payments paid to them. Separately, studies naming them as principal investigator received $669,479 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $42 2
2022 General $100 5
2021 General $173 10
2021 Research $3,995 4
2020 General $2,029 43
2020 Research $1,898 1
2019 General $3,218 209
2019 Research $1,073 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Griffin
  • Pennsylvania median
  • Middle half of Pennsylvania
  • National median

In program year 2025, general payments to Robert Griffin were reported at $0. Among 44,217 Pennsylvania profiles paid that year, the median was $168 and the middle half received between $50 and $597.

Show as a table
Year Robert Griffin Pennsylvania median Middle half National median
2019 $3,218 $156 $46–$628 $163
2020 $2,029 $109 $33–$381 $114
2021 $173 $125 $35–$469 $132
2022 $100 $136 $40–$499 $149
2023 $42 $147 $46–$523 $160
2024 $0 $156 $46–$568 $164
2025 $0 $168 $50–$597 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Planmeca USA, Inc. $1,326 1 payment
  2. Novartis Pharmaceuticals Corporation $520 30 payments
  3. Pfizer Inc. $402 36 payments
  4. Amgen Inc. $396 26 payments
  5. Genentech USA, Inc. $351 23 payments
  6. Janssen Biotech, Inc. $347 16 payments
  7. AbbVie, Inc. $291 17 payments
  8. Genzyme Corporation $225 11 payments
  9. E.R. Squibb & Sons, L.L.C. $224 14 payments
  10. UCB, Inc. $210 14 payments
  11. Other $1,269 81 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $4,202 266 payments
  2. Honoraria $1,326 1 payment
  3. Education $34 2 payments
Products named General payments · program years 2019–2023
  1. Planmeca Dental X-Ray $1,326 1 payment
  2. COSENTYX $496 29 payments
  3. SIMPONI ARIA $347 16 payments
  4. Actemra $320 21 payments
  5. XELJANZ $314 29 payments
  6. STELARA $312 14 payments
  7. Rituxan $304 20 payments
  8. Prolia $254 17 payments
  9. ORENCIA $224 14 payments
  10. Cimzia $210 14 payments
  11. Other $2,449 148 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2023
  1. Eli Lilly and Company $6,471 5 payments
  2. Eli Lilly Export S.A. Puerto Rico Branch $495 1 payment

Records

275 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record